Group items matching

in title, tags, annotations or url

The Glaucoma Foundation offers grants to researchers striving to improve the lives of glaucoma patients through novel innovations and scientific advances. The area of current focus for TGF's Grant Research program is exfoliation syndrome and exfoliation glaucoma.  The next deadline for grant applications is January 1, 2016. Initial grant funding for a one-year period is for up to $40,000; a grantee is permitted to apply for a grant renewal of up to $50,000. A renewal grant is a one year grant based upon research findings from the initial research.

The purpose of this funding opportunity announcement (FOA) in Vietnam is to ensure provision of high-quality clinical services for people living with HIV and strengthen Government of Vietnam's ability to respond to the national HIV/AIDS epidemic, as well as other infectious diseases and public health conditions. Key objectives include: * To integrate HIV QI indicators and activities into the hospital-wide general QI program * Strengthen laboratory and clinical quality management and improvement systems within the curative (e.g. hospital-based) system, including for hospital-based HIV services; * Support development of guidelines and technical standards for diagnosis, care and treatment for hepatitis, as an important co-morbidity among HIV patients.

This Funding Opportunity Announcement (FOA) requests applications for the development of medium- to high-throughput "omics" technologies that can be used to explore human pancreatic tissues with single cell- or near single cell- resolution. Successful applicants will join the Consortium on Beta cell Death and Survival (CBDS), whose mission is to identify the mechanisms of beta cell stress and destruction central to the development of Type 1 Diabetes (T1D) in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and preventing the progression towards autoimmunity. CBDS is part of the Human Islet Research Network (HIRN).

This Funding Opportunity Announcement (FOA) requests applications for the development of medium- to high-throughput "omics" technologies that can be used to explore human pancreatic tissues with single cell- or near single cell- resolution. Successful applicants will join the Consortium on Beta cell Death and Survival (CBDS), whose mission is to identify the mechanisms of beta cell stress and destruction central to the development of Type 1 Diabetes (T1D) in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and preventing the progression towards autoimmunity. 

The goal of this Funding Opportunity Announcement (FOA) is to support innovative research with human subjects to elucidate the role of gastrointestinal mucosal immunity during HIV infection, to evaluate pathophysiologic mechanisms of injury to the liver and the biliary system during HIV infection, and to conduct epidemiological studies of liver diseases and disorders in HIV patients. Proposed projects must involve individuals with HIV infection or materials or data from HIV-infected individuals.

The Medical Toxicology Foundation anticipates awarding up to $20,000 in 2015 to fund innovative projects that support the Foundation's mission of an enriched understanding, enhanced patient care, and improved dissemination of knowledge regarding toxic exposures.

The Mentored Clinical Research Award (MCRA) for new investigators is funded by a grant from the Parkinson's Disease Foundation (PDF) to the Parkinson Study Group (PSG). The PDF collaborates with the PSG to encourage the professional and scientific development of young investigators on their path to independence. To this end, this grant supports a new investigator for a one year project in patient oriented research in Parkinson's disease (PD) or other parkinsonian disorders. The new investigator works under the mentorship of an experienced investigator. Training should enhance the junior clinical research skills. The research plan should address unmet needs of people living with PD, have the potential for broad application among the PD community, and lead to advances in clinically relevant treatment options.

The AACR and its Chemistry in Cancer Research Working Group established this award in 2007 to recognize the importance of chemistry to advancements in cancer research. The award will be given for outstanding, novel and significant chemistry research, which has led to important contributions to the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer or the treatment of patients with cancer. Such research may include, but is not limited to, drug discovery and design; structural biology; proteomics, metabolomics and biological mass spectrometry; chemical aspects of carcinogenesis; imaging agents and radiotherapeutics; and chemical biology.

We fund projects at each stage of the drug development pipeline to ensure promising leads are advanced as quickly as possible. Our pre-clinical screening program breaks down barriers to entry, our academic grants focus on novel therapies, and our industry investments bring the most promising treatments to patients quickly.

The purpose of this Funding Opportunity Announcement is to solicit applications for early-stage translational research projects focused on discovery and development of novel non-traditional therapeutics that provide alternative treatment modalities for infected patients and address the growing health care threat of increasing antibiotic resistance.

The purpose of this funding opportunity announcement (FOA) is to assist the Government of Mali's National HIV-AIDS Control Program (CSLS-MOH) to develop the scientific data for decision making required for the PMTCT program, particularly as it relates to key populations (KP) such as professional sex workers, and female partners of men who have sex with men (MSM). The project also seeks to optimize the current EID (Early Infant Diagnosis) program, a component of the PMTCT program, to develop the appropriate laboratory linkages with the National Reference Laboratory in order to develop a patient focus approach. As such, the project seeks to serve as a pilot PMTCT program in a specific geographic area of Mali where synergies between existing HIV-AIDS Prevention and Care & Treatment programs can be optimized.

This Funding Opportunity Announcement (FOA) issued by the Office of Research on Women's Health (ORWH) and co-sponsoring Institutes and Centers (ICs) of the National Institutes of Health (NIH) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS), sometimes referred to as myalgic encephalomyelitis (ME), in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among patient populations, the common mechanisms influencing the multiple body systems that are affected in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of the disease process and provide evidence based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS.

The goal of this funding announcement is to establish a sustainable network of US institutions that can obtain hospitalization data and provide accurate estimates of annual influenza vaccine effectiveness (VE) to preventinfluenza-associated hospitalizations in US adult populations. Participating institutions will coordinate enrollment of adult hospitalized patients with acute respiratory illness (ARI), confirm influenza infection using sensitive laboratory-based molecular assays, and estimate VE using a test-negative study design.

In accordance with Dr. Heiser's instructions, grant funds must be used, not for treatment of patients, but for basic laboratory research directed at a better understanding of leprosy and its bacterial agent. The aspiration of the Program in 2015, is the application of the outcomes of more recent research on leprosy biomarker/diagnostic research to the global effort to truly eliminate the disease.

The intent of the NETPR Program Career Progression Award is to support independent, early-career investigators who have innovative, high-impact ideas or new technologies applicable to PD research and/or patient care. This award provides an opportunity to obtain the funding and experience necessary for productive career progression at the forefront of research specifically on non-motor aspects of PD. Preliminary data to support the feasibility and rationale of the proposed work are required. Any preliminary data provided should be from the laboratory of the PI or collaborators. 

The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients.Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials.

National Brain Tumor Society (NBTS) seeks Grant Applications in the area of discovery, development, characterization and/or validation of new, or refinement of existing, biomarkers to advance our understanding of oligoendroglioma with the goal of accelerating therapeutic development and improving patient care.

The purpose of this Funding Opportunity Announcement is to encourage research on the basic biology of the intervertebral disc and on the molecular mechanisms underlying intervertebral disc degeneration. Back/spinal pain, which is a major public health concern in the United States, is strongly associated with intervertebral disc degeneration. Acute low back pain that is serious enough to disrupt daily routines affects about 70 percent of adults sometime during their lives. In the vast majority of patients, low back pain resolves within a few weeks with conservative medical management. 

Consequently, this funding opportunity will use the investigator-initiated award mechanism to support work focused on the molecular pathogenesis of, diagnosis, and treatment of endocrine dysfunction in patients with Fanconi anemia. We expect that the nature and scope of the proposed research will vary from application to application, and it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the numbers, quality, duration, and costs of the applications received.

The purpose of this program is to develop and implement training programs to teach students in health professions (physician assistants, dentists, psychologists, pharmacists, nurses, social workers, counselors, and medical students and residents) the skills necessary to provide evidence-based screening and brief intervention and refer patients who are at risk for a substance use disorder (SUD) to appropriate treatment.